pramipexole has been researched along with vincristine in 1 studies
Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (vincristine) | Trials (vincristine) | Recent Studies (post-2010) (vincristine) |
---|---|---|---|---|---|
1,103 | 219 | 517 | 246 | 0 | 117 |
Protein | Taxonomy | pramipexole (IC50) | vincristine (IC50) |
---|---|---|---|
Tubulin beta-4A chain | Homo sapiens (human) | 0.5 | |
Tubulin beta chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-3C chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-1B chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-4A chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-4B chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-3 chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-2A chain | Homo sapiens (human) | 0.5 | |
Beta-tubulin | Leishmania donovani | 1 | |
Tubulin beta-8 chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-2B chain | Bos taurus (cattle) | 1.8 | |
Tubulin alpha-3E chain | Homo sapiens (human) | 0.5 | |
Tubulin alpha-1A chain | Homo sapiens (human) | 0.5 | |
Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8 | |
Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 1.8 | |
Tubulin alpha-1C chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-6 chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-2B chain | Homo sapiens (human) | 0.5 | |
Tubulin beta-1 chain | Homo sapiens (human) | 0.5 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for pramipexole and vincristine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |